FDAnews Drug Daily Bulletin

Claris Imports OK, ANDAs May Advance

Sept. 5, 2012
A A
The FDA has notified Indian generic-drug maker Claris Lifesciences that it can once again sell its products to the U.S. and will see its pending ANDAs addressed, the company says. The correspondence follows recent publication of a closeout letter on deviations from good manufacturing practices at the company’s Ahmedabad, India, plant.
Generic Line